AATI News

Stay up-to-date on the latest developments from Advanced Analytical Technologies, Inc., from new kits and publications to awards and new international offices.

Man reading newspaper
Page: [1]  2   3   4   5   6   > 
  • AATI Strikes Multiple New Alliances in 2017

    Published: Wednesday, January 10th, 2018
    Tags: Alliances, Corporate News

    Advanced Analytical Technologies, Inc. (AATI) entered into multiple new agreements over the course of 2017 most significantly with long- and short-read sequencer manufacturers. “Our mission is to bring unparalleled quality and service to our customers. These alliances allow AATI to fulfill its promise to help todays researchers reduce time to results through faster and more reliable QC workflows.” Said Steve Siembieda, VP of Commercialization.

  • AATI’s Mutation Screening Method for CRISPR Workflows Featured in GEN

    Published: Tuesday, November 28th, 2017
    Tags: CRISPR, Fragment Analyzer

    Integration of an accurate and efficient mutation screening method into CRISPR/Cas genome editing workflows saves researchers time and money by eliminating unnecessary sequencing.

    Genetic Engineering & Biotechnology News recently published a tutorial detailing our solution for CRISPR mutation screening and zygosity determination. Starting with the AccuCleave T7CE Kit, cleavage products are separated using the CRISPR Gel Discovery Kit on the Fragment Analyzer, followed by analysis using a custom plugin for PROSize Data Analysis Software. For more information, read the tutorial here.

  • AATI Featured in CRISPR Commentary

    Published: Tuesday, October 3rd, 2017
    Tags: CRISPR

    AATI’s own Steve Siembieda, Vice President of Commercialization, recently penned a commentary in DDNews on two primary issues in CRISPR genome editing: (1) low specificity and (2) low efficiency.  Put simply, CRISPR technology produces too many off-target mutations and does not have the success rate necessary for adoption into sensitive applications, notably the treatment of genetic illnesses.  The article went on to discuss potential remedies for low specificity and low efficiency in CRISPR workflows and the associated QC and mutation screening challenges.  The Fragment Analyzer supports these remedies and fulfills the QC and screening needs of CRISPR pipelines, accurately assessing the suitability of reagents and identifying and characterizing positive lines.

  • AATI and Illumina Partner to Promote Scalable NGS QC Solutions

    Published: Wednesday, September 13th, 2017
    Tags: Alliances, Corporate News

    Advanced Analytical Technologies, Inc (AATI) is excited to partner with Illumina to support collaborations and co-marketing activities involving our Fragment Analyzer™ Automated CE Systems for quality assessment of nucleic acids in Illumina next-generation sequencing (NGS) workflows. Assessing nucleic acid quality is essential for the success of NGS applications. The Fragment Analyzer provides a scalable method, tested by Illumina, for accurate analysis of a broad range of sample types in Illumina NGS library prep workflows, including genomic DNA, RNA, cell-free liquid biopsy, single-cell isolates, and prepared libraries before sequencing. Illumina has published an Application Note that provides an overview o

  • AATI Expands International Presence with Opening of Offices in the United Kingdom

    Published: Friday, August 11th, 2017
    Tags: Corporate News

    On the heels of opening Advanced Analytical SARL in France last year, AATI is thrilled to announce the opening of our third international office.  Located approximately 40 miles northwest of London in Milton Keynes, England, the AATI UK office will provide direct sales and support to the entire United Kingdom.  With the opening of the latest international office, AATI now provides direct sales and support to 10 countries, continuing our dedication to providing our customers with a world class experience.

Page: [1]  2   3   4   5   6   > 
Top